IMA Key Statistics, Chart & Performance
The current stock price of IMA is 6.5 USD. In the past month the price decreased by -26.07%.
IMA Latest News, Press Relases and Analysis
IMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.31 | 983.43B | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.59B | ||
| MRK | MERCK & CO. INC. | 11.64 | 254.46B | ||
| PFE | PFIZER INC | 8.02 | 145.89B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.68 | 102.62B | ||
| ZTS | ZOETIS INC | 19.53 | 54.57B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.95B | ||
| VTRS | VIATRIS INC | 4.67 | 12.54B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.52 | 11.22B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.97 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.39B |
Related stock screener links
About IMA
Company Profile
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Company Info
IMAGENEBIO INC
12526 High Bluff Drive
San Diego CALIFORNIA US
Employees: 9
Phone: 18573438292
IMAGENEBIO INC / IMA FAQ
Can you describe the business of IMAGENEBIO INC?
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
What is the stock price of IMAGENEBIO INC today?
The current stock price of IMA is 6.5 USD. The price increased by 4.67% in the last trading session.
Does IMAGENEBIO INC pay dividends?
IMA does not pay a dividend.
What is the ChartMill rating of IMAGENEBIO INC stock?
IMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists IMA stock?
IMA stock is listed on the Nasdaq exchange.
How is the market expecting IMA stock to perform?
6 analysts have analysed IMA and the average price target is 281.52 USD. This implies a price increase of 4231.08% is expected in the next year compared to the current price of 6.5.
IMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMA.
IMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMA. No worries on liquidiy or solvency for IMA as it has an excellent financial health rating, but there are worries on the profitability.
IMA Financial Highlights
Over the last trailing twelve months IMA reported a non-GAAP Earnings per Share(EPS) of -8.07. The EPS decreased by -20.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |
IMA Forecast & Estimates
6 analysts have analysed IMA and the average price target is 281.52 USD. This implies a price increase of 4231.08% is expected in the next year compared to the current price of 6.5.